Determination of blood markers and inflammation in subjects with impaired glucose tolerance;Determinación de marcadores séricos de trombosis e inflamación en sujetos con intolerancia a la glucosa: Evidencia de un estado protrombótico

Archivos de Cardiologia de Mexico

Volumn 82, Issue 1, 2012, Pages 1-6

  Lucas Luciardi, Héctor ^a   Berman, Sofia G ^a   Chain, Sergio ^a   Feldman, Gabriela ^a   Herrera, Ramón N ^a   Muntaner, Juan A ^a   del Pino, Enrique J ^a   Martínez Reding, Jesús ^b   Martínez Sánchez, Carlos R ^b  

^a Universidad Nacional de Tucuman UNT Facultad de Medicina   (Argentina)

^b INSTITUTO NACIONAL DE CARDIOLOGÍA IGNACIO CHÁVEZ   (Mexico)

Author keywords

Argentina; Fibrinolytic dysfunction; Impaired glucose tolerance; Inflammation; Prothrombotic state

Indexed keywords

C REACTIVE PROTEIN; D DIMER; FIBRINOGEN; PLASMINOGEN ACTIVATOR INHIBITOR 1; BIOLOGICAL MARKER;

ADULT; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE MARKER; FEMALE; FIBRINOLYSIS; HUMAN; IMPAIRED GLUCOSE TOLERANCE; INFLAMMATION; MALE; THROMBOSIS; BLOOD; CASE CONTROL STUDY; COMPLICATION; CROSS-SECTIONAL STUDY; GLUCOSE INTOLERANCE; MIDDLE AGED;

BIOLOGICAL MARKERS; CASE-CONTROL STUDIES; CROSS-SECTIONAL STUDIES; FEMALE; GLUCOSE INTOLERANCE; HUMANS; INFLAMMATION; MALE; MIDDLE AGED; THROMBOSIS;

EID: 84859818106     PISSN: 14059940     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (38)

1. o Edición. México:PyDesa;2011:1-18.
2. Grundy SM. Hypertriglyceridemia, atherogenic dyslipidemia and the metabolic syndrome. Am J Cardiol 1998;81:18B-25B.
3. Executive summary of the Third Report of the National Cholesterol Education Program (NCEP). Expert panel on detection, evaluation and treatmen of high blood cholesterol in adults (Adult Treatment Panel III). JAMA 2001;285:2486-2497.
4. Barbosa JB, Moura Da Silva AA, De Flores Barbosa F. Síndrome metabólico en ambulatorio cardiológico. Arq Bras Cardiol 2010;94:44-51.
5. Lakka H, Laaksonen D, Lakka T, et al. The metabolic syndrome and total and cardiovascular disease mortality in middLe-aged men. JAMA 2002;288:2709-2716.
6. Anand S, Yi Q, Gerstein H, et al. For the Study of Health Assessment and Risk in Ethnic groups (SHARE) and Study of Health Assessment and Risk Evaluation in Aboriginal Peoples (SHARE-AP) Investigators. Relationship of metabolic syndrome and fibrinolytic dysfunction to cardiovascular disease. Circulation 2003;108:420-425.
7. Festa A, D'Agostino R, Tracy RP, et al. Elevated levels of acute-phase proteins and plasminogen activator inhibitor-1 predict the development of Type 2 diabetes. The Insulin Resistance Atherosclerosis Study. Diabetes 2002;51:1131-1137.
8. Timpson NJ, Lawlor DA, Harbord RM, et al. C-reactive protein and its role in metabolic syndrome: mendelian randomisation study. The Lancet 2005;366:1954-1959.
9. Aronson D, Bartha P, Zinder O, et al. Association between fasting glucose and C reactive protein in middLe-aged subjects. Diabet Med 2004;21:39-44.
10. Temelkova-Kurktschiev T, Siegert G, Bergmann S, et al. Sub-clinical inflammation is strongly related to insulin resistance but no to impaired insulin secretion in high risk population for diabetes. Metabolism 2002;51:743-749.
11. Bartnik M, Ryden L, Ferrari R, et al. The prevalence of abnormal glucose regulation in patients with coronary artery disease across Europe. The Euro Heart Survey on Diabetes and the Heart. Eur Heart J 2004;25:1880-1890.
12. Barr EL, Zimmet PZ, Welborn, et al. Risk of cardiovascular and all-cause mortality in individuals with diabetes mellitus, impaired fasting glucose, and impaired glucose tolerance: the Australian Diabetes, Obesity, and Lifestyle Study (AusDiab). Circulation 2007;116:151-157.
13. Nathan DM, Davidson MB, Defronzo RA, et al. Impaired fasting glucose and impaired glucose tolerance implications for care. Diabetes Care 2007;30:753-759.
14. American Diabetes Association (ADA). Screening for type 2 diabetes. Diabetes Care 2003;26:S21-S24.
15. Stern MP, Williams K, Haffner SM. Identification of persons at high risk for type 2 diabetes mellitus: Do we need the oral glucose tolerance test. Ann Intern Med 2002;136:575-581.
16. Bloomgarden ZT. American Association of Clinical Endocrinologists (AACE) consensus conference on the insulin resistance syndrome: 25-26 August 2002, Washington, DC. Diabetes Care. 2003; 26(4):1297-1303
17. Alberti K, Zimmet PZ, Shaw JE. The metabolic syndrome: a new world-wide definition from the International Diabetes Federation (IDF) consensus. Lancet 2005;366:1059-1062.
18. Grundy SM, Brewer HB Jr, Cleeman JI, Smith SC Jr, Lenfant C; American Heart Association; National Heart, Lung, and Blood Institute. Definition of metabolic syndrome: Report of the National Heart, Lung, and Blood Institute/American Heart Association conference on scientific issues related to definition. Circulation. 2004;109(3):433-438.
19. Taylor H, Jacobs D, Schucker B, et al. A questionnaire for the assessment of leisure time physical activities. J Chronic Dis 1978;31:741-755.
20. Vrijkotte TG, Van Doornen LP, De Geus EJ. Work Stress and metabolic and hemostatic risk factors. Psychosom Med 1999;61:796-805.
21. Jern C, Eriksson E, Tengborn L, et al. Changes of plasma coagulation and fibrinolysis in response to mental stress. Thromb Haemost 1989;62:767-771.
22. Stratton I, AdLer A, Neil H, et al. Association of glycaemia with micro and macrovascular complications of type 2 diabetes (UKPDS). BMJ 2000;321:405-412.
23. Mannucci P, Giangrande P. Detection of prethrombotic state due to procoagulant imbalance. Eur J Haematol 1992;48:65-69.
24. Lopez Y, Paloma M, Rifon J, et al. Measurement of prethrombotic markers in the assessment of acquired hypercoagulable states. Thromb Res 1999;93:71-78.
25. Stec J, Silbershatz H, Tofler G, et al. Association of fibrinogen with cardiovascular risk factors and cardiovascular disease in the Framingham Offspring population. Circulation 2000;102:1634-1638.
26. Folsom AR, Wu KK, Davis CE, et al. Population correlates of plasma fibrinogen and factor VII, putative cardiovascular risk factors. Atherosclerosis 1991;91:191-205.
27. Danesh J, Collms R, Appleby P, et al. Association of fibrinogen, C-reactive protein, albumin, or leukocyte count with coronary heart disease. Meta-analysis of prospective studies. JAMA 1998; 279:1477-1482.
28. Fibrinogen Studies Collaboration. Collaborative meta-analysis of prospective observational studies of plasma fibrinogen and cardiovascular disease. Eur J Cardiovasc Rehabil 2004;11:9-17.
29. Lowe GD. Circulating inflammatory markers and risks of cardiovascular and non-cardiovascular disease. J Thromb Haemost 2005;3:1618-1627.
30. Baker I, Pickering J, Elwood P, et al. Fibrinogen, viscosity and white blood cell count predict myocardyal, but not cerebral infarction: Evidence from the Caerphilly and Speedwell cohort. Thromb Haemost 2002;87:421-425.
31. Kohler HP, Grant PJ. Mechanisms of disease: plasminogen-activator inhibitor type 1 and coronary artery disease. N Engl J Med 2000;342:1792-1801.
32. Sakkinen PA, Wahl P, Cushman M, et al. Clustering of procoagulation, inflammation and fibrinolysis variables with metabolic factor in insulin resistance syndrome. Am J Epidemiol 2000;152:897-907.
33. Lindahl B, Nilsson T, Jansson J, et al. Improved fibrinolysis by intense lifestyle intervention: a randomized trial in subjects with impaired glucose tolerance. J Intern Med 1999;246:105-112.
34. Temelkova-Kurktschiev T, Siegert G, Bergmann S, et al. Sub-clinical inflammation is strongly related to insulin resistance but no to impaired insulin secretion in high risk population for diabetes. Metabolism 2002;51:743-749.
35. Aronson D, Bartha P, Zinder O, et al. Association between fasting glucose and C reactive protein in middLe-aged subjects. Diabet Med 2004;21:39-44.
36. Ridker P, Wilson PW, Grundy SM. Should C-reactive protein be added to metabolic syndrome and to the asssment of global cardiovascular risk?. Circulation 2004;109:2818-2825.
37. Festa A, D'Agostino R Jr, Tracy R, et al. Elevated levels of acute-phase proteins and plasminogen activator inhibitor-1 predict the development of type 2 diabetes. The Insulin Resistance Atherosclerosis Study (IRAS). Diabetes 2002;51:1131-1137.
38. Hu FB, Meigs JB, Li TY, et al. Inflammatory markers and risk of development type 2 diabetes in women. Diabetes 2004;53:693-700.